drugset
drugset / Trial / NCT07484113

IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

NCT07484113 ↗

Phase 1 Not yet recruiting 10 enrolled Stanford University
Non-randomizedSequentialOpen-labelSupportive care

Summary

A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with belumosudil-refractory chronic graft-versus-host disease (cGVHD).

Timeline

Start
2026-07
Primary completion
2028-05
Completion
2028-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarilumab Monoclonal antibody 150 mg Subcutaneous
Subject Sarilumab Monoclonal antibody 200 mg Subcutaneous
Background Belumosudil Small molecule 200 mg Oral

Indications

chronic graft versus host disease